Overview

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Status:
Recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

The main objective of this study is to investigate the safety and tolerability of si-544. Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system (immune cells) that have been chronically activated by the disease. Likewise, the effect of si-544 on inflammatory responses in the body triggered by the disease and other disease symptoms will be investigated.

Phase:

Phase 1

Details

Lead Sponsor:

selectION Therapeutics GmbH

Collaborator:

FGK Clinical Research GmbH